U.S. AI-enabled Ophthalmic Diagnostic Devices Market (2026 - 2033)

U.S. AI-enabled Ophthalmic Diagnostic Devices Market Summary

The U.S. AI-enabled ophthalmic diagnostic devices market size was valued at USD 64.3 million in 2025 and is projected to grow from USD 72.5 million in 2026 to USD 267.2 million by 2033, at a CAGR of 20.5% from 2026 to 2033. The market is experiencing rapid growth as healthcare providers increasingly adopt artificial intelligence to address rising demand for early detection of retinal diseases, improve screening efficiency, and overcome shortages of ophthalmologists in primary care settings. AI-enabled retinal imaging systems have evolved from decision-support tools to autonomous diagnostic platforms capable of identifying diabetic retinopathy and other sight-threatening diseases without specialist interpretation.

One of the primary drivers of market growth is the increasing prevalence of diabetes and diabetic retinopathy (DR) across the U.S., creating a substantial need for scalable screening solutions. According to the CDC's Vision and Eye Health Surveillance System (VEHSS), an estimated 9.6 million Americans were living with diabetic retinopathy in 2021, including approximately 1.84 million individuals with vision-threatening diabetic retinopathy. The prevalence is projected to increase substantially, with 14.7 million Americans expected to be affected by 2050, highlighting the growing burden of diabetes-related vision impairment in the U.S. This growing disease burden is encouraging healthcare systems to implement AI-enabled retinal screening technologies that can accurately identify patients requiring specialist referral while improving screening compliance in primary care settings.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Technological innovation and continued FDA clearances are further accelerating market expansion. In May 2024, the FDA cleared the Optomed Aurora handheld fundus camera integrated with AEYE Health's autonomous AI software (AEYE-DS), enabling portable diabetic retinopathy screening in virtually any healthcare setting across the U.S. The handheld system performs autonomous image analysis within approximately one minute, allowing screening to move beyond traditional eye clinics into primary care offices, pharmacies, and community health centers. This approval significantly broadened the accessibility of AI-enabled ophthalmic diagnostics and strengthened the commercialization of portable retinal imaging solutions in the U.S.

Moreover, AI-powered portable screening solutions are increasingly supporting early detection in primary care settings, reducing dependence on specialist availability while expanding access to vision care in underserved and remote communities. These innovations are strengthening the role of autonomous retinal diagnostics within routine diabetes management and preventive healthcare. To strengthen this trend, research presented at ENDO 2025 by investigators from the University of Texas Health Science Center at Houston introduced the Simple Mobile AI Retina Tracker (SMART), an AI-powered mobile retinal screening application capable of detecting and staging diabetic retinopathy with more than 99% accuracy in under one second. Designed to operate on internet-enabled devices, including basic smartphones, the solution enables primary care providers to incorporate retinal screening into routine diabetes care while expanding access to high-quality ophthalmic assessments in regions with limited specialist availability.

The market is also benefiting from growing clinical acceptance and supportive diabetes care guidelines. The American Diabetes Association (ADA) Standards of Care 2025 recognize FDA-authorized autonomous AI systems, including AEYE-DS (AEYE Health), EyeArt (Eyenuk), and LumineticsCore (Digital Diagnostics), as validated alternatives for diabetic retinopathy screening when appropriately implemented. The guidelines specifically recommend the use of retinal photography with remote reading or FDA-authorized AI algorithms to improve access to diabetic retinopathy screening, particularly in settings where access to eye care specialists is limited.

In addition, the ADA notes that prospective multicenter clinical trials have demonstrated the diagnostic accuracy of each of these autonomous AI platforms, supporting their integration into routine diabetes care. These AI-enabled screening services are also covered by most U.S. insurance plans, further reducing financial barriers to adoption and facilitating broader implementation across primary care and endocrinology practices. As healthcare providers continue to prioritize preventive care, early disease detection, and workflow automation, AI-enabled ophthalmic diagnostic devices are expected to play an increasingly important role in improving vision care outcomes across the U.S.

Market Dynamics

The U.S. AI-enabled ophthalmic diagnostic devices industry is witnessing robust growth as hospitals, ophthalmology clinics, optometry practices, academic medical centers, and primary care facilities increasingly adopt artificial intelligence (AI)-powered diagnostic technologies to improve the early detection, diagnosis, and management of vision-threatening eye diseases. The market comprises a broad range of AI-enabled ophthalmic diagnostic solutions, including AI-integrated fundus cameras, optical coherence tomography (OCT) systems, retinal imaging platforms, visual field analyzers, corneal topographers, and cloud-based image analysis software that assist clinicians in detecting retinal and optic nerve abnormalities with greater speed and accuracy. These technologies are increasingly being integrated into clinical workflows to enhance diagnostic efficiency, support clinical decision-making, reduce interpretation variability, and enable large-scale screening programs.

Market Characteristics

The AI-enabled ophthalmic diagnostic devices industry is moderately consolidated, with leading companies such as Toku Eyes, Digital Diagnostics Inc., Eyenuk, Inc., AEYE Health, Optos, Notal Vision, Inc., Carl Zeiss AG, Canon Medical Systems, Topcon Corporation, Optomed holding significant market positions across AI-assisted retinal imaging, optical coherence tomography (OCT), fundus photography, and autonomous ophthalmic screening solutions. These companies offer comprehensive portfolios comprising AI-enabled fundus cameras, OCT systems, retinal imaging devices, visual field analyzers, corneal imaging systems, cloud-based image management platforms, and artificial intelligence software designed to improve the detection and diagnosis of ophthalmic diseases. Their solutions support the identification and monitoring of diabetic retinopathy (DR), glaucoma, age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vascular diseases, and other vision-threatening ocular conditions through automated image analysis and clinical decision support.

The U.S. AI-enabled ophthalmic diagnostic devices industry is characterized by a high degree of innovation, driven by rapid advancements in artificial intelligence, deep learning algorithms, cloud-based image analytics, and multimodal ophthalmic imaging technologies. Manufacturers are increasingly developing AI-enabled diagnostic platforms capable of automatically detecting and classifying retinal and optic nerve diseases from fundus photographs and optical coherence tomography (OCT) images with high accuracy, enabling earlier disease detection and improved clinical decision-making. For instance, in May 2024 AEYE Health received FDA clearance for AEYE-DS autonomous AI diagnostic system for use with the Optomed Aurora handheld fundus camera.

To learn more about this report, Download Free Sample Report

The market is witnessing a significant increase in strategic partnerships and collaborations as ophthalmic device manufacturers, AI companies, healthcare technology providers, academic research institutions, and healthcare delivery networks work together to accelerate innovation, improve clinical decision support, and expand access to AI-enabled eye disease screening. These collaborations are focused on integrating AI algorithms with ophthalmic imaging devices, enhancing interoperability with cloud-based healthcare platforms and electronic health record (EHR) systems, validating AI technologies through clinical research, and expanding the adoption of autonomous screening solutions across primary care, optometry, and ophthalmology settings.

The market operates within a stringent regulatory framework primarily overseen by the U.S. FDA, which ensures the safety, effectiveness, quality, and clinical performance of ophthalmic diagnostic devices and artificial intelligence-enabled Software as a Medical Device (SaMD). As AI technologies become increasingly integrated into retinal imaging systems, optical coherence tomography (OCT), fundus cameras, and clinical decision support platforms, regulatory oversight has intensified to address challenges related to algorithm transparency, clinical validation, cybersecurity, real-world performance monitoring, and lifecycle management of AI models. For instance, in January 2025, the FDA issued the draft guidance titled "Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations," outlining recommendations for manufacturers regarding clinical validation, transparency, risk management, change control, cybersecurity, and post-market monitoring throughout the lifecycle of AI-enabled medical devices.

The U.S. AI-enabled ophthalmic diagnostic devices industry faces competition from several conventional diagnostic modalities and alternative eye examination approaches that may reduce the adoption of AI-enabled diagnostic technologies, particularly in healthcare facilities with budget constraints or limited digital infrastructure. Traditional ophthalmic diagnostic methods, including manual slit-lamp biomicroscopy, indirect ophthalmoscopy, optical coherence tomography (OCT) interpretation by ophthalmologists, fundus photography without AI-assisted analysis, visual field testing, and fluorescein angiography, continue to serve as the standard of care across many hospitals and ophthalmology practices. These conventional diagnostic approaches are supported by well-established clinical workflows, extensive physician familiarity, and broad reimbursement, making them a preferred choice for many providers despite requiring specialist interpretation and longer assessment times.

The market is experiencing significant regional expansion as ophthalmic device manufacturers, AI companies, healthcare providers, and integrated delivery networks continue to broaden access to AI-enabled eye care solutions across hospitals, ophthalmology clinics, optometry practices, primary care centers, retail health clinics, and community healthcare settings. Companies are increasingly expanding their commercial footprint by deploying AI-powered retinal imaging systems, cloud-based diagnostic platforms, and autonomous screening technologies beyond specialized ophthalmology practices to improve access to early eye disease detection in underserved and rural populations.

Analyst Perspective

The U.S. market has emerged as one of the fastest-growing segments within the broader ophthalmic diagnostics and digital healthcare industry, driven by the increasing prevalence of vision-threatening eye diseases, growing demand for early disease detection, expanding adoption of artificial intelligence in clinical practice, and continuous advancements in ophthalmic imaging technologies. Ophthalmic diagnostics are increasingly evolving from conventional image acquisition toward intelligent, AI-assisted diagnostic ecosystems that enable automated image interpretation, clinical decision support, and predictive disease analytics. As healthcare providers prioritize early intervention and precision medicine, AI-enabled diagnostic devices are becoming an integral component of modern eye care delivery across hospitals, ophthalmology clinics, optometry practices, and teleophthalmology networks throughout the U.S.

Component Insights

The fundus cameras segment dominated the market and accounted for the largest share of 38.2% in 2025. The segment's leadership is primarily driven by the widespread installation of advanced fundus cameras across hospitals, specialty clinics, and diagnostic centers. These imaging platforms serve as the foundation for AI-enabled diagnostics by generating the high-quality retinal and anterior segment images required for automated detection of diabetic retinopathy (DR). Recent industry developments further highlight the growth of segment. For instance, in April 2025, the FDA granted 510(k) clearance for the CLARUS 700 from Carl Zeiss Meditec, an ultra-widefield retinal imaging system incorporating AI-enabled capabilities, reflecting continued innovation in advanced ophthalmic imaging technologies for clinical diagnosis.

The OCT/OCTA systems segment is expected to witness the significant CAGR over the forecast period, owing to the rapid adoption of artificial intelligence algorithms that enhance the detection, classification, and monitoring of retinal diseases while leveraging existing ophthalmic imaging infrastructure. AI software can be integrated in OCT/OCTA systems through cloud-based or on-premise platforms, enabling healthcare providers to improve diagnostic accuracy without substantial capital investment in new equipment. Key market players are increasingly focusing on strategic initiatives to strengthen their market presence and accelerate the adoption of AI-enabled ophthalmic diagnostic solutions across the U.S. For instance, in May 2025, Topcon Healthcare announced the acquisition of RetInSight GmbH, an AI software company specializing in OCT image analysis. The acquisition aims to integrate advanced AI algorithms into Topcon's Harmony digital health platform, enabling automated interpretation of retinal OCT scans and enhancing clinical decision support across ophthalmic practices.

Application Insights

The diabetic retinopathy detection dominated the market and held the largest revenue share in 2025. The growth is primarily attributed to the growing burden of diabetes and diabetic eye disease across the U.S., creating a strong need for efficient and scalable screening solutions. Increasing awareness regarding the importance of annual diabetic eye screening, coupled with expanding teleophthalmology programs and the integration of AI into routine retinal imaging workflows, has further accelerated adoption of AI-enabled diabetic retinopathy detection solutions. Moreover, the availability of FDA-authorized autonomous AI systems capable of delivering rapid and accurate screening results has enabled healthcare providers to improve screening efficiency, particularly in primary care settings and underserved communities where access to ophthalmologists remains limited. The American Diabetes Association (ADA) Standards of Care 2025 continued to recognize FDA-authorized autonomous AI systems, including LumineticsCore, EyeArt, and AEYE-DS, as validated options for diabetic retinopathy screening when implemented in appropriate clinical settings. These developments highlight the growing adoption of AI software, which improves screening efficiency, reduces physician workload, and expands access to retinal disease detection.

The age-related macular degeneration (AMD) segment is expected to witness a significant CAGR over the forecast period. The growth is driven by the rapidly aging U.S. population, increasing prevalence of retinal disorders, and growing demand for early disease detection to prevent irreversible vision loss. AI-enabled ophthalmic diagnostic devices, particularly those integrated with optical coherence tomography (OCT) and fundus imaging systems, are increasingly being adopted to assist clinicians in identifying early structural changes associated with AMD, improving diagnostic accuracy, and enabling timely intervention. According to the National Eye Institute (NEI), nearly 20 million people in the U.S. are living with some form of AMD, making it one of the leading causes of vision impairment among older adults.

End Use Insights

The specialty clinics segment dominated the market in 2025. The growth is attributed to the high volume of ophthalmic consultations, widespread availability of advanced retinal imaging infrastructure, and increasing integration of artificial intelligence into routine clinical workflows. Specialty clinics serve as the primary settings for the diagnosis and management of diabetic retinopathy (DR), age-related macular degeneration (AMD), glaucoma, diabetic macular edema (DME), and other vision-threatening disorders, resulting in substantial demand for AI-enabled fundus cameras, OCT/OCTA systems, and diagnostic software. To further strengthen AI adoption and improve clinical workflow efficiency, leading industry participants are actively pursuing strategic collaborations with healthcare technology providers. For instance, in January 2026, LumineticsCore announced a partnership with Artisight to integrate its FDA-authorized autonomous AI software for diabetic retinopathy screening into Artisight's smart hospital platform. The collaboration enables hospitals and clinics to incorporate AI-driven retinal screening into routine clinical workflows, improving screening efficiency and expanding access to early detection services.

To learn more about this report, Download Free Sample Report

The home care segment is anticipated to grow at fastest rate over the forecast period. The growth is driven by the increasing adoption of teleophthalmology, remote patient monitoring, and AI-enabled software solutions that facilitate early detection and follow-up of eye diseases outside traditional clinical settings. While advanced ophthalmic imaging devices such as fundus cameras and OCT/OCTA systems continue to be predominantly used in hospitals and specialty clinics, growing digital health infrastructure and cloud-based AI platforms are enabling patients to participate in remote vision monitoring and virtual eye care programs under the supervision of eye care professionals. The rising prevalence of chronic diseases such as diabetes, coupled with the need for regular retinal assessments and improved access to eye care for elderly individuals and patients in underserved areas, is further supporting the adoption of home-based ophthalmic monitoring solutions. In addition, increasing investments in connected healthcare technologies and remote care models are expected to accelerate the integration of AI-enabled ophthalmic software into home care setting.

Key U.S. AI-enabled Ophthalmic Diagnostic Devices Company Insight

The U.S. market is highly competitive, characterized by the presence of established ophthalmic imaging companies, artificial intelligence software developers, and digital health technology providers focused on expanding their clinical capabilities and strengthening their market position. Market participants are continuously investing in research and development to enhance the accuracy, speed, and clinical utility of AI-powered diagnostic platforms for the early detection and management of ocular diseases.

Key U.S. AI-enabled Ophthalmic Diagnostic Devices Companies

• Digital Diagnostics Inc.

• Eyenuk, Inc.

• AEYE Health

• Notal Vision, Inc.

• Carl Zeiss AG

• Optos

• Canon Medical Systems

• Topcon Corporation

• Optomed

• Heidelberg Engineering

Recent Development

• In October 2025, Topcon Healthcare signed a definitive agreement to acquire Toku Inc., an AI health technology company, to strengthen its "Healthcare from the Eye" strategy through advanced retinal image-based diagnostics. The acquisition integrates Toku's AI platforms into Topcon's connected care ecosystem to expand non-invasive screening for cardiovascular disease, biological aging, and chronic kidney disease across primary care, eyecare, and telehealth settings.

• In July 2025, AEYE Health partnered with Ford Medical to expand the availability of its FDA-cleared AEYE-DS autonomous AI diabetic eye screening solution across pharmacies and non-acute care centers throughout the U.S. Through the partnership, Ford Medical will distribute the AI-powered screening platform, enabling providers to offer immediate, reimbursable diabetic retinopathy screening at the point of care without requiring specialist interpretation, improving access to early detection for U.S. patients.

U.S. AI-enabled Ophthalmic Diagnostic Devices Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. AI-enabled ophthalmic diagnostic devices market report based on component, application, and end use:

• Component Outlook (Revenue, USD Unit, 2021 - 2033)

  • Fundus Cameras  

  • OCT/OCTA Systems  

  • Ultra-widefield Imaging Systems  

  • Slit Lamp Imaging Systems  

• Application Outlook (Revenue, USD Unit, 2021 - 2033)

  • Diabetic Retinopathy Detection      

  • Age-related Macular Degeneration (AMD)      

  • Glaucoma Detection      

  • Diabetic Macular Edema      

  • Others      

• End Use Outlook (Revenue, USD Unit, 2021 - 2033)

  • Hospitals

  • Specialty Clinics

  • Diagnostic Centers      

  • Home Care      

  • Academic Centers

Research Methodology

The U.S. AI-enabled ophthalmic diagnostic devices market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each U.S. AI-enabled ophthalmic diagnostic devices segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations